Mass Spectrometry as a tool for the Bioanalysis of Antibody-Drug Conjugates (ADCs)

Stéphane Frécinaux
Arnaud Delobel
EBF Open Symposium 2017

Antibody-Drug Conjugates (ADCs) are antibodies engineered to deliver a cytotoxic agent specifically to tumor cells expressing a defined antigen. Compared to the bioanalysis of small molecules or recombinant proteins, the bioanalysis of ADCs is much more challenging due to the complexity of the drug. Multiple species are present in the circulation that can provide additional information on clinial safety and efficacy.

We present in this poster the strategy used for the bioanalysis of antibody-drug conjugates, combining immunoassays and LC/MS. A focus is put on mass spectrometry techniques and their use for the quantification of the antibody, the determination of the drug-to-antibody ratio and the quantification of the small molecule species.